688639 华恒生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.5785.0828.63127.15424.030
总资产报酬率 ROA (%)0.7132.4604.23114.97518.281
投入资产回报率 ROIC (%)0.8372.9145.13118.74422.267

边际利润分析
销售毛利率 (%)20.96221.26724.92440.51638.659
营业利润率 (%)4.9814.5309.15226.35924.111
息税前利润/营业总收入 (%)7.1865.91310.28526.28023.703
净利润/营业总收入 (%)4.8654.3288.47423.04122.510

收益指标分析
经营活动净收益/利润总额(%)97.16093.72379.90396.89795.154
价值变动净收益/利润总额(%)-0.788-0.7290.4240.5032.183
营业外收支净额/利润总额(%)-6.986-3.2631.037-0.9150.274

偿债能力分析
流动比率 (X)1.2131.0930.8430.6262.220
速动比率 (X)0.7740.6960.5890.4911.871
资产负债率 (%)55.71054.42448.72454.01626.908
带息债务/全部投入资本 (%)44.38040.77334.88036.982-0.233
股东权益/带息债务 (%)116.478133.597173.836156.433-38,972.633
股东权益/负债合计 (%)80.07784.214105.49785.190271.431
利息保障倍数 (X)2.8393.8759.913164.477-50.050

营运能力分析
应收账款周转天数 (天)31.26434.91243.76747.00355.343
存货周转天数 (天)85.62275.01669.72656.51250.000